Primary Navigation for the CDC Website
CDC en EspaƱol
Vaccine Safety
E-Mail Icon E-mail this page
Printer Friendly Icon Printer-friendly version
 Vaccine Safety Basics
bullet Information for Parents
bullet Why It's Important to Monitor Vaccine Safety
bullet How Vaccines Are Tested and Monitored
bullet Common Questions
bullet Vaccine Safety Concerns
bullet History of Vaccine Safety

 Public Health Activities
bullet Vaccine Adverse Event Reporting System (VAERS)
bullet Vaccine Safety Datalink (VSD) Project
bullet Clinical Immunization Safety Assessment (CISA) Network
bullet Brighton Collaboration
bullet Vaccine Technology
bullet Emergency Preparedness
bullet Publications
bullet Scientific Agenda

About the Immunization Safety Office

As a leader in immunization safety surveillance and research, CDC's Immunization Safety Office (ISO) plays a vital role in assuring vaccine safety. Sound immunization policies affecting our nation's health depend upon continuous monitoring of vaccines and ongoing assessment of immunization benefits and risks. Using a multifaceted approach, CDC identifies possible vaccine side effects, conducts epidemiological studies to determine whether a particular adverse event is caused by a specific vaccine, helps determine the appropriate public health response to vaccine safety concerns, and communicates the benefits and risks of vaccines to the public, media, and healthcare communities. A robust and transparent immunization safety monitoring and research system must exist to ensure safe and effective vaccines and maintain public confidence in immunizations.


Vaccine Adverse Event Reporting System (VAERS): VAERS is a public health activity authorized by the National Childhood Vaccine Injury Act of 1986 and administered by CDC in collaboration with the U.S. Food and Drug Administration. VAERS serves as an early-warning system to detect problems that may be related to vaccines. VAERS provides postmarketing surveillance on childhood and adolescent vaccines that protect against 16 diseases and adult vaccines that protect against 13 diseases. In 2005, VAERS reports indicated a possible association between Guillain-Barre syndrome (GBS) and receipt of meningococcal conjugate vaccine (MCV4, Menactra®).

By October 2006, ISO had led an investigation of 18 confirmed cases of GBS following Menactra immunization to prevent meningococcal disease and published three MMWR articles on this issue. Initial investigations suggested there may be a small increased risk of GBS following Menactra immunization, but CDC is unable to determine whether Menactra increases the risk of GBS in persons who receive the vaccine. CDC continues to recommend routine vaccination with Menactra for those at increased risk.

Vaccine Safety Datalink (VSD) Project: Through the VSD Project, ISO staff collaborates with eight managed care organizations to collect vaccination data on more than 5.5 million people annually. This collaboration resulted in 10 journal articles published in 2006.

The Brighton Collaboration: ISO staff works with scientists from 71 countries to develop standardized case definitions and guidelines for vaccine adverse events. Through the Brighton Collaboration, 16 case definitions were completed in 2006.

Clinical Immunization Safety Assessment (CISA): ISO staff collaborates with six academic centers to investigate pathophysiologic mechanisms and biologic risks of adverse events following immunization. CISA established an IRB-approved registry and repository to enroll people experiencing adverse events following immunization and store specimens for future studies. CISA enrolled and evaluated new cases of GBS following Menactra and new cases of illness following yellow fever vaccine.

Future Directions

Research Planned on Potential Association of Vaccine Adverse Events and Human Genetic Variations
In 2006, ISO received $1.5 million additional funding from Congress to study risk factors for serious adverse reactions, develop screening tools to identify children at high risk for developing serious vaccine adverse reactions, and develop effective treatments and interventions for children experiencing severe adverse reactions. CDC is finalizing the request for proposals that will be issued through this new extramural immunization safety research activity.

Contact Us

Centers for Disease Control and Prevention
Immunization Safety Office
1600 Clifton Road NE
MS D-26
Atlanta, GA 30333
(404) 639-8256
(404) 639-8834 (fax)

Page last reviewed: September 24, 2008
Page last updated: January 23, 2008
Content source: Immunization Safety Office

  Home | Policies and Regulations | Disclaimer | e-Government | FOIA | Contact Us
Safer, Healthier People

Centers for Disease Control and Prevention
1600 Clifton Rd, Atlanta, GA 30333, U.S.A.
Public Inquiries: 1-800-CDC-INFO (232-4636); 1-888-232-6348 (TTY)
USA.govDHHS Department of Health
and Human Services